Prognostic Factor | 5y-LRFS (%) | P value | 5y-OS (%) | P value |
---|---|---|---|---|
Age | Â | 0.601 | Â | 0.926 |
 <28 yr | 82.2 |  | 41.1 |  |
 ≥ 28 yr | 56.8 |  | 41.4 |  |
Gender | Â | 0.825 | Â | 0.318 |
 Male | 71.7 |  | 34.2 |  |
 Female | 64.8 |  | 50.1 |  |
Histology | Â | 0.276 | Â | 0.267 |
 Embryonal | 57.3 |  | 27.3 |  |
 Alveolar | 81.4 |  | 64.3 |  |
Primary site | Â | 0.385 | Â | 0.421 |
 Parameningeal | 58.9 |  | 36.5 |  |
 Non- Parameningeal | 85.2 |  | 48.9 |  |
 Primary tumor size |  | 0.047 |  | 0.142 |
 ≤ 5 cm | 94.7 |  | 58.0 |  |
 > 5 cm | 50.0 |  | 30.9 |  |
Nodal status | Â | 0.029 | Â | 0.478 |
 N0 | 85.0 |  | 44.0 |  |
 N1 | 50.0 |  | 34.7 |  |
Disease status | Â | 0.908 | Â | 0.205 |
 Local-regional (M0) | 69.8 |  | 45.0 |  |
 Distant (M1) | Not reached |  | 0 |  |
IRS pretreatment staging | Â | 0.766 | Â | 0.205 |
 Stage I + II | 78.4 |  | 53.6 |  |
 Stage III + IV | 59.9 |  | 32.8 |  |
IRS postsurgical grouping | Â | 0.385 | Â | 0.333 |
 Group I + II | 65.3 |  | 43.7 |  |
 Group III + IV | 71.9 |  | 38.3 |  |
Surgery margins | Â | 0.162 | Â | 0.301 |
 Negative (R0) | 100.0 |  | 83.3 |  |
 Positive (R1/2) | 58.4 |  | 40.9 |  |
Responses to chemotherapy | Â | 0.922 | Â | 0.692 |
 CR + PR | 55.0 |  | 25.7 |  |
 SD + PD | 70.5 |  | 44.3 |  |
Chemoradiotherapy types | Â | 0.770 | Â | 0.896 |
 CCRT | 67.1 |  | 37.0 |  |
 No-CCRT | 76.2 |  | 42.9 |  |
Local treatment patterns | Â | 0.049 | Â | 0.027 |
 Surgery + RT | 73.6 |  | 52.4 |  |
 RT | 64.2 |  | 24.5 |  |